Pradaxa® vs Warfarin...
November 1, 2014 - Featured , In the News / Politics By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk… |
|
The Importance of Organ Donation: Perspectives and the ...
March 1, 2014 - Featured , Professional Advice / Opinions By: James Schurr, PharmD Candidate c/o 2014 and Jennifer Miao, PharmD Candidate c/o 2014 With very special thanks to Jessica Melore and Jennifer McDermott, PharmD, BCPS of NewYork-Presbyterian Hospital – Jessica Melore was 16 years old, a senior in high school, and co-captain of the tennis team when her life took a drastic turn. While… |
|
Direct Association of HIV and Early Kidney Damage in Wo...
January 1, 2014 - Featured , In the News / Politics By: Elizabeth Kopec, PharmD Candidate c/o 2014, South University School of Pharmacy at Columbia, SC – Human immunodeficiency virus (HIV) is a global pandemic, with approximately 35.3 million people infected in 2012. The United States currently has 1.3 million people living with HIV, with 20,000 deaths occurring every year due to acquired immune deficiency syndrome… |
|
New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who… |
|
Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are… |
|
Indications for Dialysis: A Mnemonic And Explanation...
August 1, 2012 - Clinical , Featured By: Neal Shah, Co-Editor-in-Chief – Dialysis is the removal of substances from intravascular circulation by filtration.1 Typically, dialysis is ordered when kidney function declines to 10–15% of normal function.2 The National Kidney Foundation’s Kidney Disease Outcome Quality Initiative (K/DOQI) recommends that planning for dialysis begin when patients reach chronic kidney disease stage 4, which is… |
|
The Pathology of Pure Red Cell Aplasia...
July 1, 2012 - Clinical By: Neal Shah, Co Editor-In-Chief – Pure Red Cell Aplasia (PRCA), also known as erythroblastopenia, is characterized by a suppression of erythrocytes in the bone marrow. It is a peculiar oddity that the bone marrow’s progenitor cells still differentiate into white blood cells and platelets.1 PRCA has idiopathic, viral, auto-immune, and genetic etiologies. Diamond-Blackfan syndrome… |
|
Xigris: A Worldwide Withdrawal...
January 1, 2012 - Clinical , In the News / Politics By: Khilna Patel, Pharm.D. Candidate c/o 2012 – On October 25 of this year, Eli Lilly and Company announced a worldwide market withdrawal of Xigris (drotrecogin alfa), a drug previously indicated to treat severe sepsis in high-risk patients. Drotrecogin alfa is a recombinant form of human activated protein C. The efficacy of drotrecogin alfa was… |